AirSculpt Technologies reported second quarter fiscal 2026 results ending June 30, 2026, with revenue declining 3% to $42.9 million and a net loss of $1.1 million compared to $0.6 million in the prior year period. Same-center case volume increased 1.0%, while Adjusted EBITDA fell to $4.9 million from $5.8 million. The company reaffirmed its full-year revenue guidance at the lower end of $151–$157 million but reduced adjusted EBITDA outlook to approximately $12–$14 million. Balance sheet improvements included raising $5.0 million via an at-the-market offering and reducing gross debt by approximately $30 million to $44.2 million, with cash increasing to $18.8 million. Additionally, the company amended its term loan agreement on August 7, 2026, extending maturity to November 2027 and requiring a $5.0 million payment schedule. AirSculpt Technologies operates in the aesthetic medicine industry, providing premium body contouring procedures.